{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:08:01Z","timestamp":1790784481282,"version":"4.1.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100024157","name":"Neurelis, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100024157","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40263-023-01060-1","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T08:02:06Z","timestamp":1707984126000},"page":"125-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Benzodiazepines for the Treatment of Seizure Clusters"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5831-8690","authenticated-orcid":false,"given":"Patricia E.","family":"Penovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6389-2638","authenticated-orcid":false,"given":"Vikram R.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6240-3521","authenticated-orcid":false,"given":"Lucretia","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8788-0722","authenticated-orcid":false,"given":"Enrique","family":"Carrazana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-0606","authenticated-orcid":false,"given":"Adrian L.","family":"Rabinowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"1060_CR1","doi-asserted-by":"publisher","first-page":"821","DOI":"10.15585\/mmwr.mm6631a1","volume":"66","author":"MM Zack","year":"2017","unstructured":"Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy - United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66:821\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1060_CR2","first-page":"1","volume":"57","author":"R Kobau","year":"2008","unstructured":"Kobau R, Zahran H, Thurman DJ, et al. Epilepsy surveillance among adults\u201319 States, Behavioral Risk Factor Surveillance System, 2005. MMWR Surveill Summ. 2008;57:1\u201320.","journal-title":"MMWR Surveill Summ"},{"issue":"Suppl 1","key":"1060_CR3","first-page":"S6","volume":"63","author":"SR Haut","year":"2022","unstructured":"Haut SR, Nabbout R. Recognizing seizure clusters in the community: The path to uniformity and individualization in nomenclature and definition. Epilepsia. 2022;63(Suppl 1):S6\u201313.","journal-title":"Epilepsia"},{"key":"1060_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.seizure.2018.05.013","volume":"68","author":"S Jafarpour","year":"2019","unstructured":"Jafarpour S, Hirsch LJ, Gainza-Lein M, et al. Seizure cluster: definition, prevalence, consequences, and management. Seizure. 2019;68:9\u201315.","journal-title":"Seizure."},{"key":"1060_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40263-022-00940-2","volume":"36","author":"R Kienitz","year":"2022","unstructured":"Kienitz R, Kay L, Beuchat I, et al. Benzodiazepines in the management of seizures and status epilepticus: a review of routes of delivery, pharmacokinetics, efficacy, and tolerability. CNS Drugs. 2022;36:951\u201375.","journal-title":"CNS Drugs"},{"key":"1060_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/NRL.0000000000000140","volume":"22","author":"PE Penovich","year":"2017","unstructured":"Penovich PE, Buelow J, Steinberg K, et al. Burden of seizure clusters on patients with epilepsy and caregivers: survey of patient, caregiver, and clinician perspectives. Neurologist. 2017;22:207\u201314.","journal-title":"Neurologist"},{"key":"1060_CR7","doi-asserted-by":"crossref","unstructured":"Hatoum HT, Arcona S, Mao J, et al. Real-world antiseizure medication treatment outcomes in drug-resistant focal epilepsy patients. Epilepsia Open. 2023;8:1556\u201365.","DOI":"10.1002\/epi4.12845"},{"key":"1060_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40263-018-0544-2","volume":"32","author":"J Kadel","year":"2018","unstructured":"Kadel J, Bauer S, Hermsen AM, et al. Use of Emergency Medication in Adult Patients with Epilepsy: A Multicentre Cohort Study from Germany. CNS Drugs. 2018;32:771\u201381.","journal-title":"CNS Drugs"},{"key":"1060_CR9","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/epi.16847","volume":"62","author":"J Cloyd","year":"2021","unstructured":"Cloyd J, Haut S, Carrazana E, et al. Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters. Epilepsia. 2021;62:846\u201356.","journal-title":"Epilepsia"},{"key":"1060_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108013","volume":"121","author":"P Penovich","year":"2021","unstructured":"Penovich P, Wheless JW, Hogan RE, et al. Examining the patient and caregiver experience with diazepam nasal spray for seizure clusters: results from an exit survey of a phase 3, open-label, repeat-dose safety study. Epilepsy Behav. 2021;121: 108013.","journal-title":"Epilepsy Behav"},{"key":"1060_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108989","volume":"138","author":"TC Meng","year":"2023","unstructured":"Meng TC, Szaflarski JP, Chen L, et al. Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: results of a phase 3, open-label extension trial. Epilepsy Behav. 2023;138: 108989.","journal-title":"Epilepsy Behav"},{"key":"1060_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107836","volume":"117","author":"J Buchhalter","year":"2021","unstructured":"Buchhalter J, Shafer PO, Buelow JM, et al. Preferred practices for rescue treatment of seizure clusters: a consensus-driven, multi-stakeholder approach. Epilepsy Behav. 2021;117: 107836.","journal-title":"Epilepsy Behav"},{"key":"1060_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.yebeh.2015.04.022","volume":"47","author":"RS Fisher","year":"2015","unstructured":"Fisher RS, Bartfeld E, Cramer JA. Use of an online epilepsy diary to characterize repetitive seizures. Epilepsy Behav. 2015;47:66\u201371.","journal-title":"Epilepsy Behav"},{"key":"1060_CR14","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1212\/WNL.51.5.1274","volume":"51","author":"JJ Cereghino","year":"1998","unstructured":"Cereghino JJ, Mitchell WG, Murphy J, et al. Treating repetitive seizures with a rectal diazepam formulation: a randomized study. The North American Diastat Study Group. Neurology. 1998;51:1274\u201382.","journal-title":"Neurology"},{"key":"1060_CR15","unstructured":"US Food and Drug Administration. Search orphan drug designatations and approvals. 2021. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=61591. Accessed 3 Sep 2021."},{"key":"1060_CR16","volume-title":"Diastat\u00ae C-IV (diazepam rectal gel). Full Prescribing Information","author":"Bausch Health US, LLC","year":"2023","unstructured":"Bausch Health US, LLC. Diastat\u00ae C-IV (diazepam rectal gel). Full Prescribing Information. Bridgewater: Bausch Health US, LLC; 2023."},{"key":"1060_CR17","volume-title":"VALTOCO\u00ae (diazepam nasal spray). Full Prescribing Information","author":"Neurelis, Inc","year":"2023","unstructured":"Neurelis, Inc. VALTOCO\u00ae (diazepam nasal spray). Full Prescribing Information. San Diego: Neurelis Inc; 2023."},{"key":"1060_CR18","volume-title":"Nayzilam\u00ae (midazolam nasal spray). Full Prescribing Information","author":"UCB, Inc","year":"2023","unstructured":"UCB, Inc. Nayzilam\u00ae (midazolam nasal spray). Full Prescribing Information. Smyrna: UCB Inc; 2023."},{"key":"1060_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.0013-9580.2005.29004.x","volume":"46","author":"SR Haut","year":"2005","unstructured":"Haut SR, Shinnar S, Moshe SL. Seizure clustering: risks and outcomes. Epilepsia. 2005;46:146\u20139.","journal-title":"Epilepsia"},{"key":"1060_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.yebeh.2018.09.035","volume":"88","author":"K Detyniecki","year":"2018","unstructured":"Detyniecki K, O\u2019Bryan J, Choezom T, et al. Prevalence and predictors of seizure clusters: a prospective observational study of adult patients with epilepsy. Epilepsy Behav. 2018;88:349\u201356.","journal-title":"Epilepsy Behav"},{"key":"1060_CR21","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1111\/j.1528-1157.1999.tb02047.x","volume":"40","author":"WG Mitchell","year":"1999","unstructured":"Mitchell WG, Conry JA, Crumrine PK, et al. An open-label study of repeated use of diazepam rectal gel (Diastat) for episodes of acute breakthrough seizures and clusters: safety, efficacy, and tolerance. North American Diastat Group. Epilepsia. 1999;40:1610\u20137.","journal-title":"Epilepsia"},{"key":"1060_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.643916","volume":"12","author":"M Ochoa-Urrea","year":"2021","unstructured":"Ochoa-Urrea M, Lacuey N, Vilella L, et al. Seizure clusters, seizure severity markers, and SUDEP risk. Front Neurol. 2021;12: 643916.","journal-title":"Front Neurol"},{"key":"1060_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/WCO.0000000000000177","volume":"28","author":"SR Haut","year":"2015","unstructured":"Haut SR. Seizure clusters: characteristics and treatment. Curr Opin Neurol. 2015;28:143\u201350.","journal-title":"Curr Opin Neurol"},{"key":"1060_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-94-017-8914-1_9","volume":"813","author":"R Dingledine","year":"2014","unstructured":"Dingledine R, Varvel NH, Dudek FE. When and how do seizures kill neurons, and is cell death relevant to epileptogenesis? Adv Exp Med Biol. 2014;813:109\u201322.","journal-title":"Adv Exp Med Biol"},{"key":"1060_CR25","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1212\/01.wnl.0000180685.84547.7f","volume":"65","author":"SR Haut","year":"2005","unstructured":"Haut SR, Lipton RB, LeValley AJ, et al. Identifying seizure clusters in patients with epilepsy. Neurology. 2005;65:1313\u20135.","journal-title":"Neurology"},{"key":"1060_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106748","volume":"177","author":"S Chung","year":"2021","unstructured":"Chung S, Szaflarski JP, Choi EJ, et al. A systematic review of seizure clusters: prevalence, risk factors, burden of disease and treatment patterns. Epilepsy Res. 2021;177: 106748.","journal-title":"Epilepsy Res"},{"key":"1060_CR27","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/epi.17588","volume":"64","author":"AG Herzog","year":"2023","unstructured":"Herzog AG, Carrazana E, Rabinowicz AL. A comparison of statistical versus clinical classifiers of seizure clustering in women with catamenial and noncatamenial epilepsy. Epilepsia. 2023;64:1507\u201315.","journal-title":"Epilepsia"},{"key":"1060_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.seizure.2021.04.022","volume":"89","author":"SR Dewar","year":"2021","unstructured":"Dewar SR, Ranit L, Pieters HC. Reciprocal burden: adults with drug-resistant epilepsy reflect upon informal caregiver support. Seizure. 2021;89:85\u201392.","journal-title":"Seizure."},{"key":"1060_CR29","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/epi.17237","volume":"63","author":"EC Wirrell","year":"2022","unstructured":"Wirrell EC, Nabbout R, Scheffer IE, et al. Methodology for classification and definition of epilepsy syndromes with list of syndromes: report of the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63:1333\u201348.","journal-title":"Epilepsia"},{"key":"1060_CR30","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1111\/epi.17340","volume":"63","author":"E Faught","year":"2022","unstructured":"Faught E. Economic aspects of treating seizure clusters. Epilepsia. 2022;63:S45-54.","journal-title":"Epilepsia"},{"key":"1060_CR31","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1212\/WNL.0000000000003629","volume":"88","author":"AK Birnbaum","year":"2017","unstructured":"Birnbaum AK, Leppik IE, Svensden K, et al. Prevalence of epilepsy\/seizures as a comorbidity of neurologic disorders in nursing homes. Neurology. 2017;88:750\u20137.","journal-title":"Neurology"},{"key":"1060_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/jnnp.56.2.149","volume":"56","author":"P Klenerman","year":"1993","unstructured":"Klenerman P, Sander JW, Shorvon SD. Mortality in patients with epilepsy: a study of patients in long term residential care. J Neurol Neurosurg Psychiatry. 1993;56:149\u201352.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1060_CR33","doi-asserted-by":"publisher","unstructured":"Hartman AL, Devore CD, Section on Neurology, American Academy of Pediatrics, et al. Rescue medicine for epilepsy in education settings. Pediatrics. 2016;137. https:\/\/doi.org\/10.1542\/peds.2015-3876.","DOI":"10.1542\/peds.2015-3876"},{"key":"1060_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108390","volume":"125","author":"R Chhabra","year":"2021","unstructured":"Chhabra R, Gupta R, Gupta LK. Intranasal midazolam versus intravenous\/rectal benzodiazepines for acute seizure control in children: a systematic review and meta-analysis. Epilepsy Behav. 2021;125: 108390.","journal-title":"Epilepsy Behav"},{"key":"1060_CR35","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1056\/NEJM199806253382602","volume":"338","author":"FE Dreifuss","year":"1998","unstructured":"Dreifuss FE, Rosman NP, Cloyd JC, et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med. 1998;338:1869\u201375.","journal-title":"N Engl J Med"},{"key":"1060_CR36","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1007\/s10072-021-05468-9","volume":"42","author":"D Samanta","year":"2021","unstructured":"Samanta D. Rescue therapies for seizure emergencies: current and future landscape. Neurol Sci. 2021;42:4017\u201327.","journal-title":"Neurol Sci"},{"key":"1060_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/epi.16449","volume":"61","author":"RE Hogan","year":"2020","unstructured":"Hogan RE, Gidal BE, Koplowitz B, et al. Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers. Epilepsia. 2020;61:455\u201364.","journal-title":"Epilepsia"},{"key":"1060_CR38","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1528-1167.2009.02333.x","volume":"51","author":"GJ de Haan","year":"2010","unstructured":"de Haan GJ, van der Geest P, Doelman G, et al. A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations. Epilepsia. 2010;51:478\u201382.","journal-title":"Epilepsia"},{"key":"1060_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1212\/CPJ.0000000000000099","volume":"5","author":"SK Agarwal","year":"2015","unstructured":"Agarwal SK, Cloyd JC. Development of benzodiazepines for out-of-hospital management of seizure emergencies. Neurol Clin Pract. 2015;5:80\u20135.","journal-title":"Neurol Clin Pract."},{"key":"1060_CR40","volume-title":"School nursing evidence-based practice clinical guideline: students with seizures and epilepsy","author":"AM Lepkowski","year":"2018","unstructured":"Lepkowski AM. School nursing evidence-based practice clinical guideline: students with seizures and epilepsy. Silver Spring: National Association of School Nurses; 2018."},{"key":"1060_CR41","unstructured":"US Food and Drug Administration. Clinical Superiority Findings. 2019. https:\/\/www.fda.gov\/industry\/designating-orphan-product-drugs-and-biological-products\/clinical-superiority-findings. Accessed 23 June 2020."},{"key":"1060_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2022.100581","volume":"21","author":"S Chung","year":"2023","unstructured":"Chung S, Peters JM, Detyniecki K, et al. The nose has it: opportunities and challenges for intranasal drug administration for neurologic conditions including seizure clusters. Epilepsy Behav Rep. 2023;21: 100581.","journal-title":"Epilepsy Behav Rep."},{"key":"1060_CR43","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1111\/epi.16300","volume":"60","author":"JW Wheless","year":"2019","unstructured":"Wheless JW, Meng TC, Van Ess PJ, et al. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: an open-label extension trial. Epilepsia. 2019;60:1809\u201319.","journal-title":"Epilepsia"},{"key":"1060_CR44","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1111\/epi.15159","volume":"60","author":"K Detyniecki","year":"2019","unstructured":"Detyniecki K, Van Ess PJ, Sequeira DJ, et al. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters-a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019;60:1797\u2013808.","journal-title":"Epilepsia"},{"key":"1060_CR45","unstructured":"US Food and Drug Administration. Valtoco (diazepam nasal spray) NDA Approval. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/211635Orig1s000Approv.pdf. Accessed 28 Oct 2022."},{"key":"1060_CR46","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1111\/epi.17041","volume":"62","author":"JW Wheless","year":"2021","unstructured":"Wheless JW, Miller I, Hogan RE, et al. Final results from a phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy. Epilepsia. 2021;62:2485\u201395.","journal-title":"Epilepsia"},{"key":"1060_CR47","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40268-021-00360-5","volume":"21","author":"AL Rabinowicz","year":"2021","unstructured":"Rabinowicz AL, Carrazana E, Maggio ET. Improvement of intranasal drug delivery with Intravail\u00ae alkylsaccharide excipient as a mucosal absorption enhancer aiding in the treatment of conditions of the central nervous system. Drugs R D. 2021;21:361\u20139.","journal-title":"Drugs R D."},{"key":"1060_CR48","unstructured":"Cook DF, Gustin RM, Misra SN, et al. Effectiveness of diazepam nasal spray does not vary across times of day associated with meals and fasting in patients with seizure clusters: post hoc results from a long-term, open-label safety study. AES; 2022 December 2-6; Nashville, TN."},{"key":"1060_CR49","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1212\/WNL.96.15_supplement.1753","volume":"96","author":"J Wheless","year":"2021","unstructured":"Wheless J, Sperling M, Liow K, et al. Safety profile of Valtoco\u00ae (diazepam nasal spray) in patients with epilepsy: final results from a phase 3, open-label, 12-month repeat dose safety study (1753). Neurology. 2021;96:1753.","journal-title":"Neurology"},{"key":"1060_CR50","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/epi.16506","volume":"61","author":"RE Hogan","year":"2020","unstructured":"Hogan RE, Tarquinio D, Sperling MR, et al. Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal\/peri-ictal) and nonseizure (interictal) conditions: a phase 1, open-label study. Epilepsia. 2020;61:935\u201343.","journal-title":"Epilepsia"},{"key":"1060_CR51","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/epi.17177","volume":"63","author":"MR Sperling","year":"2022","unstructured":"Sperling MR, Wheless JW, Hogan RE, et al. Use of second doses of Valtoco\u00ae (diazepam nasal spray) across 24 hours after the initial dose for out-of-hospital seizure clusters: results from a phase 3, open-label, repeat-dose safety study. Epilepsia. 2022;63:836\u201343.","journal-title":"Epilepsia"},{"key":"1060_CR52","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/epi.17249","volume":"63","author":"GD Cascino","year":"2022","unstructured":"Cascino GD, Tarquinio D, Wheless JW, et al. Lack of clinically relevant differences in safety and pharmacokinetics after second-dose administration of intranasal diazepam within 4 h for acute treatment of seizure clusters: a population analysis. Epilepsia. 2022;63:1714\u201323.","journal-title":"Epilepsia"},{"key":"1060_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2022.04.011","volume":"132","author":"D Tarquinio","year":"2022","unstructured":"Tarquinio D, Dlugos D, Wheless JW, et al. Safety of diazepam nasal spray in children and adolescents with epilepsy: results from a long-term phase 3 safety study. Pediatr Neurol. 2022;132:50\u20135.","journal-title":"Pediatr Neurol"},{"key":"1060_CR54","unstructured":"ClinicalTrials.gov. Pharmacokinetics study of VALTOCO\u00ae in pediatric subjects with epilepsy (NCT05076838). 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05076838. Accessed 16 Aug 2022."},{"key":"1060_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109248","volume":"144","author":"JM Peters","year":"2023","unstructured":"Peters JM, Puri V, Segal E, et al. Concomitant cannabidiol does not impact safety and effectiveness of diazepam nasal spray for seizure clusters: Post hoc analysis of a phase 3 safety study. Epilepsy Behav. 2023;144: 109248.","journal-title":"Epilepsy Behav"},{"key":"1060_CR56","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/epi.16901","volume":"62","author":"EB Segal","year":"2021","unstructured":"Segal EB, Tarquinio D, Miller I, et al. Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: an interim subgroup analysis from a phase 3, long-term, open-label safety study. Epilepsia. 2021;62:1442\u201350.","journal-title":"Epilepsia"},{"key":"1060_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107898","volume":"118","author":"B Vazquez","year":"2021","unstructured":"Vazquez B, Wheless J, Desai J, et al. Lack of observed impact of history or concomitant treatment of seasonal allergies or rhinitis on repeated doses of diazepam nasal spray administered per seizure episode in a day, safety, and tolerability: interim results from a phase 3, open-label, 12-month repeat-dose safety study. Epilepsy Behav. 2021;118: 107898.","journal-title":"Epilepsy Behav"},{"key":"1060_CR58","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/epi4.12494","volume":"6","author":"I Miller","year":"2021","unstructured":"Miller I, Wheless JW, Hogan RE, et al. Consistent safety and tolerability of Valtoco\u00ae (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: interim results from a phase 3, long-term, open-label, repeat-dose safety study. Epilepsia Open. 2021;6:504\u201312.","journal-title":"Epilepsia Open."},{"key":"1060_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108811","volume":"134","author":"JA Cramer","year":"2022","unstructured":"Cramer JA, Faught E, Davis C, et al. Quality-of-life results in adults with epilepsy using diazepam nasal spray for seizure clusters from a long-term, open-label safety study. Epilepsy Behav. 2022;134: 108811.","journal-title":"Epilepsy Behav"},{"key":"1060_CR60","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/epi.17385","volume":"63","author":"SN Misra","year":"2022","unstructured":"Misra SN, Sperling MR, Rao VR, et al. Significant improvements in SEIzure interVAL (time between seizure clusters) across time in patients treated with diazepam nasal spray as intermittent rescue therapy for seizure clusters. Epilepsia. 2022;63:2684\u201393.","journal-title":"Epilepsia"},{"key":"1060_CR61","unstructured":"Neurelis Inc. VALTOCO. Instructions for use for 5 mg and 10 mg doses. 2020. https:\/\/www.valtoco.com\/sites\/default\/files\/VALTOCO_Instructions_For_Use.pdf. Accessed 3 Sep 2020."},{"key":"1060_CR62","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1111\/epi.17341","volume":"63","author":"B Gidal","year":"2022","unstructured":"Gidal B, Detyniecki K. Rescue therapies for seizure clusters: pharmacology and target of treatments. Epilepsia. 2022;63:S34\u201344.","journal-title":"Epilepsia"},{"key":"1060_CR63","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/archpediatrics.2010.130","volume":"164","author":"M Holsti","year":"2010","unstructured":"Holsti M, Dudley N, Schunk J, et al. Intranasal midazolam vs. rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med. 2010;164:747\u201353.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"1060_CR64","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pediatrneurol.2005.09.006","volume":"34","author":"M Bhattacharyya","year":"2006","unstructured":"Bhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs. rectal diazepam in acute childhood seizures. Pediatr Neurol. 2006;34:355\u20139.","journal-title":"Pediatr Neurol"},{"key":"1060_CR65","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1053\/seiz.2000.0425","volume":"9","author":"M Scheepers","year":"2000","unstructured":"Scheepers M, Scheepers B, Clarke M, et al. Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy? Seizure. 2000;9:417\u201322.","journal-title":"Seizure."},{"key":"1060_CR66","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1002\/acn3.50932","volume":"6","author":"L Kay","year":"2019","unstructured":"Kay L, Merkel N, von Blomberg A, et al. Intranasal midazolam as first-line inhospital treatment for status epilepticus: a pharmaco-EEG cohort study. Ann Clin Transl Neurol. 2019;6:2413\u201325.","journal-title":"Ann Clin Transl Neurol"},{"key":"1060_CR67","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-020-00720-w","volume":"34","author":"A von Blomberg","year":"2020","unstructured":"von Blomberg A, Kay L, Knake S, et al. Efficacy, tolerability, and safety of concentrated intranasal midazolam spray as emergency medication in epilepsy patients during video-EEG monitoring. CNS Drugs. 2020;34:545\u201353.","journal-title":"CNS Drugs"},{"key":"1060_CR68","volume-title":"Midazolam injection (midazolam injection) Full Prescribing Information","author":"Hospira, Inc","year":"2023","unstructured":"Hospira, Inc. Midazolam injection (midazolam injection) Full Prescribing Information. Lake Forest: Hospira Inc; 2023."},{"key":"1060_CR69","volume-title":"Klonopin (clonazepam). Full Prescribing Information","author":"Genentech USA, Inc","year":"2021","unstructured":"Genentech USA, Inc. Klonopin (clonazepam). Full Prescribing Information. South San Francisco: Genentech USA Inc; 2021."},{"key":"1060_CR70","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1177\/0883073810368312","volume":"25","author":"MM Troester","year":"2010","unstructured":"Troester MM, Hastriter EV, Ng YT. Dissolving oral clonazepam wafers in the acute treatment of prolonged seizures. J Child Neurol. 2010;25:1468\u201372.","journal-title":"J Child Neurol"},{"key":"1060_CR71","volume-title":"Ativan (Lorazepam tablets). Full Prescribing Information","author":"Bausch Health US L","year":"2023","unstructured":"Bausch Health US L. Ativan (Lorazepam tablets). Full Prescribing Information. Bridgewater: Bausch Health US, LLC; 2023."},{"key":"1060_CR72","volume-title":"Lorazepam oral concentrate Full prescribing information. Full prescribing information","author":"Akorn","year":"2022","unstructured":"Akorn. Lorazepam oral concentrate. Full prescribing information. Gurnee: Akorn Operating Company LLC; 2022."},{"key":"1060_CR73","volume-title":"ATIVAN (lorazepam injection). Full Prescribing Information","author":"Hikma Pharmaceuticals USA Inc","year":"2021","unstructured":"Hikma Pharmaceuticals USA Inc. ATIVAN (lorazepam injection). Full Prescribing Information. Berkeley Heights: Hikma Pharmaceuticals USA Inc.; 2021."},{"key":"1060_CR74","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.1528-1167.2010.02949.x","volume":"52","author":"R Arya","year":"2011","unstructured":"Arya R, Gulati S, Kabra M, et al. Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. Epilepsia. 2011;52:788\u201393.","journal-title":"Epilepsia"},{"key":"1060_CR75","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3897\/folmed.63.e60938","volume":"63","author":"N Rudra","year":"2021","unstructured":"Rudra N, Ghosh T, Roy UK. A comparative study on intranasal versus intravenous lorazepam in the management of acute seizure in children. Folia Med (Plovdiv). 2021;63:958\u201364.","journal-title":"Folia Med (Plovdiv)."},{"key":"1060_CR76","unstructured":"Laboratorios Lesvi SL. Buccolam summary of product characteristics (midazolam hydrochloride oromucosal solution). Summary of Product Characteristics. Barcelona, Spain: Laboratorios Lesvi, S.L.; 2023."},{"key":"1060_CR77","unstructured":"National Institute for Health and Care Excellence. Epilepsies: diagnosis and management. 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553536\/. Accessed"},{"key":"1060_CR78","doi-asserted-by":"publisher","first-page":"106866","DOI":"10.1016\/j.yebeh.2019.106866","volume":"107","author":"G Capovilla","year":"2020","unstructured":"Capovilla G, Nistico R, Magrelli A. Reply to the article \u201cManagement of status epilepticus in adults. Position paper of the Italian League against Epilepsy.\u201d Epilepsy Behav. 2020;107:106866.","journal-title":"Epilepsy Behav"},{"key":"1060_CR79","unstructured":"European Medicines Agency. European Medicines Agency gives first positive opinion for paediatric-use marketing authorisation. 2011. https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-gives-first-positive-opinion-paediatric-use-marketing-authorisation. Accessed 22 June 2023."},{"key":"1060_CR80","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2165\/11209350-000000000-00000","volume":"26","author":"LJ Scott","year":"2012","unstructured":"Scott LJ, Lyseng-Williamson KA, Garnock-Jones KP. Oromucosal midazolam: a guide to its use in paediatric patients with prolonged acute convulsive seizures. CNS Drugs. 2012;26:893\u20137.","journal-title":"CNS Drugs"},{"key":"1060_CR81","unstructured":"European Medicines Agency. Buccolam. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/buccolam. Accessed 11 May 2023."},{"key":"1060_CR82","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1111\/epi.16696","volume":"61","author":"S Seinfeld","year":"2020","unstructured":"Seinfeld S, Gelfand MA, Heller AH, et al. Safety and tolerability associated with chronic intermittent use of diazepam buccal film in adult, adolescent, and pediatric patients with epilepsy. Epilepsia. 2020;61:2426\u201334.","journal-title":"Epilepsia"},{"key":"1060_CR83","unstructured":"European Medicines Agency. Nasolam and associated names. 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/nasolam-associated-names. Accessed 25 May 2023."},{"key":"1060_CR84","volume-title":"Nasolam (Midazolam nasal spray). Summary of Product Characteristics","author":"BV Medir Europe","year":"2022","unstructured":"Medir Europe BV. Nasolam (Midazolam nasal spray). Summary of Product Characteristics. Medir Europe B; 2022."},{"key":"1060_CR85","unstructured":"Electronic Medicines Compendium. Diazepam Desitin 5 mg rectal solution. 2019. https:\/\/www.medicines.org.uk\/emc\/product\/2997\/smpc. Accessed 8 Sep 2021."},{"key":"1060_CR86","unstructured":"Electronic Medicines Compendium. Diazepam RecTubes 10 mg Rectal Solution. 2020. https:\/\/www.medicines.org.uk\/emc\/product\/6799\/smpc. Accessed 7 Sep 2021."},{"key":"1060_CR87","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.yebeh.2016.07.018","volume":"63","author":"SR Haut","year":"2016","unstructured":"Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in seizure emergencies: a systematic review. Epilepsy Behav. 2016;63:109\u201317.","journal-title":"Epilepsy Behav"},{"key":"1060_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108264","volume":"123","author":"P Penovich","year":"2021","unstructured":"Penovich P, Glauser T, Becker D, et al. Recommendations for development of acute seizure action plans (ASAPs) from an expert panel. Epilepsy Behav. 2021;123: 108264.","journal-title":"Epilepsy Behav"},{"issue":"Suppl 1","key":"1060_CR89","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1528-1167.2006.00666.x","volume":"47","author":"EC Wirrell","year":"2006","unstructured":"Wirrell EC. Epilepsy-related injuries. Epilepsia. 2006;47(Suppl 1):79\u201386.","journal-title":"Epilepsia"},{"key":"1060_CR90","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11940-007-0011-8","volume":"9","author":"JJ Cereghino","year":"2007","unstructured":"Cereghino JJ. Identification and treatment of acute repetitive seizures in children and adults. Curr Treat Options Neurol. 2007;9:249\u201355.","journal-title":"Curr Treat Options Neurol"},{"key":"1060_CR91","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41582-022-00664-3","volume":"18","author":"RJ Burman","year":"2022","unstructured":"Burman RJ, Rosch RE, Wilmshurst JM, et al. Why won\u2019t it stop? The dynamics of benzodiazepine resistance in status epilepticus. Nat Rev Neurol. 2022;18:428\u201341.","journal-title":"Nat Rev Neurol"},{"key":"1060_CR92","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s40120-023-00515-3","volume":"12","author":"DA Becker","year":"2023","unstructured":"Becker DA, Wheless JW, Sirven J, et al. Treatment of seizure clusters in epilepsy: a narrative review on rescue therapies. Neurol Ther. 2023;12:1439\u201355.","journal-title":"Neurol Ther."},{"key":"1060_CR93","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1528-1167.2011.03179.x","volume":"52","author":"PR Camfield","year":"2011","unstructured":"Camfield PR, Gibson PA, Douglass LM. Strategies for transitioning to adult care for youth with Lennox-Gastaut syndrome and related disorders. Epilepsia. 2011;52:21\u20137.","journal-title":"Epilepsia"},{"key":"1060_CR94","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.yebeh.2008.05.018","volume":"13","author":"JW Wheless","year":"2008","unstructured":"Wheless JW, Manjunath R, Phelps SJ, et al. Seizure emergency plans: patient results from a cross-sectional epilepsy survey. Epilepsy Behav. 2008;13:489\u201393.","journal-title":"Epilepsy Behav"},{"key":"1060_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.109002","volume":"140","author":"ST Herman","year":"2023","unstructured":"Herman ST, Detyniecki K, O\u2019Hara K, et al. Written seizure action plans for adult patients with epilepsy: distilling insights from emergency action plans for other chronic conditions. Epilepsy Behav. 2023;140: 109002.","journal-title":"Epilepsy Behav"},{"key":"1060_CR96","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1177\/0883073819846810","volume":"34","author":"DVF Albert","year":"2019","unstructured":"Albert DVF, Moreland JJ, Salvator A, et al. Seizure action plans for pediatric patients with epilepsy: a randomized controlled trial. J Child Neurol. 2019;34:666\u201373.","journal-title":"J Child Neurol"},{"key":"1060_CR97","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1111\/j.1528-1157.1999.tb01607.x","volume":"40","author":"SR Haut","year":"1999","unstructured":"Haut SR, Shinnar S, Moshe SL, et al. The association between seizure clustering and convulsive status epilepticus in patients with intractable complex partial seizures. Epilepsia. 1999;40:1832\u20134.","journal-title":"Epilepsia"},{"key":"1060_CR98","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.eplepsyres.2009.08.006","volume":"87","author":"C Martinez","year":"2009","unstructured":"Martinez C, Sullivan T, Hauser WA. Prevalence of acute repetitive seizures (ARS) in the United Kingdom. Epilepsy Res. 2009;87:137\u201343.","journal-title":"Epilepsy Res"},{"key":"1060_CR99","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4065\/84.6.495","volume":"84","author":"KH Noe","year":"2009","unstructured":"Noe KH, Drazkowski JF. Safety of long-term video-electroencephalographic monitoring for evaluation of epilepsy. Mayo Clin Proc. 2009;84:495\u2013500.","journal-title":"Mayo Clin Proc"},{"key":"1060_CR100","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1212\/WNL.0000000000000623","volume":"83","author":"AG Herzog","year":"2014","unstructured":"Herzog AG, Frye CA, Progesterone Trial Study Group. Allopregnanolone levels and seizure frequency in progesterone-treated women with epilepsy. Neurology. 2014;83:345\u20138.","journal-title":"Neurology"},{"key":"1060_CR101","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1111\/epi.13465","volume":"57","author":"AA Asadi-Pooya","year":"2016","unstructured":"Asadi-Pooya AA, Nei M, Sharan A, et al. Seizure clusters in drug-resistant focal epilepsy. Epilepsia. 2016;57:e187\u201390.","journal-title":"Epilepsia"},{"key":"1060_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106330","volume":"163","author":"S Chiang","year":"2020","unstructured":"Chiang S, Haut SR, Ferastraoaru V, et al. Individualizing the definition of seizure clusters based on temporal clustering analysis. Epilepsy Res. 2020;163: 106330.","journal-title":"Epilepsy Res"},{"key":"1060_CR103","unstructured":"National Institute for Health and Care Excellence. Epilepsies: diagnosis and management: Clinical guideline CG137, 2021."},{"key":"1060_CR104","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.3390\/jcm10081754","volume":"10","author":"S Almohaish","year":"2021","unstructured":"Almohaish S, Sandler M, Brophy GM. Time is brain: acute control of repetitive seizures and status epilepticus using alternative routes of administration of benzodiazepines. J Clin Med. 2021;10:1754.","journal-title":"J Clin Med"},{"key":"1060_CR105","doi-asserted-by":"crossref","unstructured":"Gidal B, Welty T, Cokley J, et al. Opportunities for community pharmacists to counsel patients with epilepsy and seizure clusters to overcome barriers and foster appropriate treatment. J Pharm Pract. 2022;37:190\u20137.","DOI":"10.1177\/08971900221126570"},{"key":"1060_CR106","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2147\/NDT.S376104","volume":"18","author":"AL Rabinowicz","year":"2022","unstructured":"Rabinowicz AL, Faught E, Cook DF, et al. Implications of seizure-cluster treatment on healthcare utilization: use of approved rescue medications. Neuropsychiatr Dis Treat. 2022;18:2431\u201341.","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01060-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01060-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01060-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T17:08:38Z","timestamp":1708535318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01060-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01060-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"19 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Neurelis, Inc. (San Diego, CA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr Penovich has served on speakers\u2019 bureaus for Jazz, Neurelis, Inc., and UCB and is an advisor to Jazz, LVIS Corporation, and Neurelis, Inc. Dr Rao has served as a consultant for NeuroPace, Inc., manufacturer of the RNS System. Ms Long is a consultant for Neurelis, Inc., SK Life Science, and Supernus Pharmaceuticals and is a speaker for LivaNova. Dr Carrazana is an employee of and has received stock and stock options from Neurelis, Inc. Dr Rabinowicz is an employee and has received stock options from Neurelis, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors were involved in the conception, design, review of literature, and drafting of the manuscript and critically reviewed and revised the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}